Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib Therapy - PubMed
3 hours ago
- #Proteinuria
- #Lenvatinib
- #Hypertension
- Lenvatinib is used to treat several malignancies, with proteinuria being a frequent adverse event.
- The study aimed to identify risk factors for severe proteinuria (UPCR ≥3.5 g/gCre) in patients with thyroid cancer, hepatocellular carcinoma, and endometrial cancer.
- Of 131 patients, 26.0% developed UPCR ≥3.5 g/gCre, with the highest rate in thyroid cancer patients (45.5%).
- Initial lenvatinib dose ≥20 mg/day and grade 3 hypertension post-treatment were significant risk factors for severe proteinuria.
- The findings highlight the need for intensive blood pressure management and regular UPCR monitoring during lenvatinib therapy.